Drug intelligence / Profile preview

BMD-1171

Development stage: Preclinical
Lead developer: BiologicsMD
Modality: Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BMD-1171 is an antibody fusion protein developed by BiologicsMD, Inc. It is primarily indicated for the treatment of **Androgenetic Alopecia** and is currently in the **preclinical** phase of development. The drug targets skin and musculoskeletal diseases.

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)COL1 (Collagen type I)

Beyond the preview

Go deeper on BMD-1171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMD-1171.

Explore the full profile